A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. [electronic resource]
Producer: 20160328Description: 102 p. digitalISSN:- 1479-5876
- CA-125 Antigen -- immunology
- Clinical Trials, Phase I as Topic -- methods
- Cytotoxicity, Immunologic
- Female
- Humans
- Immunotherapy, Adoptive
- Interleukin-12 -- metabolism
- Membrane Proteins -- immunology
- Models, Immunological
- Neoplasm Recurrence, Local -- immunology
- Ovarian Neoplasms -- immunology
- Receptors, Antigen -- immunology
- T-Lymphocytes -- immunology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.